Research summary ·
Does Intensive Therapy Targeting Modifiable Risk Factors Prevent Diabetic Neuropathy in Adults with Type 2 Diabetes? A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review pooled trials that aimed to prevent nerve damage from type 2 diabetes. The nerve problem is called diabetic peripheral neuropathy. The trials targeted blood sugar, blood fats, blood pressure, smoking and lifestyle. Some used several steps together. The team found 1287 articles. Only some gave data that could be used.
What they found
Tight blood sugar control showed no clear difference in nerve damage. One trial, BARI-2D, caused most of the differences between studies. Without it, the result was still little to no change. In BARI-2D, an insulin-sensitizing strategy may have lowered nerve damage. This was seen whatever the HbA1c level. Single-study evidence suggests blood pressure lowering and multi-step care may help.
What it means for patients
The authors say blood sugar intensity may make little or no difference. They say the BARI-2D finding needs more study. They say the single-study hints also need more rigorous research.
Why it is not certain yet
Certainty was low for the BARI-2D and single-study findings. Some findings rest on one study. One trial drove the differences between studies. That trial compared drug types, not blood sugar targets. The abstract says only some articles gave usable data.
Source
Does Intensive Therapy Targeting Modifiable Risk Factors Prevent Diabetic Neuropathy in Adults with Type 2 Diabetes? A Systematic Review and Meta-analysis of Randomized Clinical Trials.
PubMed · PMID 42831957We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Type 2 diabetes publications